"Our mission is to support
you in the development of
next-generation radiopharmaceutical
technology."
Radiopharmium provides expert consulting and innovative solutions for the development and production of radiopharmaceuticals.
Expertise
Dr Louis Allott is an expert in radiochemistry and radiopharmaceutical development with over 14 years of academic and industry experience. He has a strong track record of innovative research in radiopharmaceutical development and production (for preclinical and clinical studies) and collaborates with leading pharmaceutical companies, research institutions, and healthcare providers.
Louis has developed advanced diagnostic and therapeutic radiopharmaceuticals, contributing to clinical evaluation, pipeline acceleration, and the generation of valuable intellectual property. He has played critical roles in establishing and operating radiopharmaceutical facilities in the UK for R&D and clinical manufacture.
Motivated by a commitment to advancing healthcare, he founded Radiopharmium Limited in December 2024 to provide specialist consulting services that support the development and translation of next-generation radiopharmaceutical technologies.
Portfolio
Radiopharmium works with a diverse range of clients to accelerate radiopharmaceutical innovation and delivery through tailored expertise. A selection of our clients are shown below:
Molecular Imaging Research Centre (MIRC) -
Daisy Appeal Charity, Hull, UK.
We are working with the Daisy Appeal Charity to establish and operationalise a state-of-the-art, research-focused GMP radiopharmaceutical manufacturing facility. This initiative will enhance the UK's capacity for innovative radiopharmaceutical development and support translational research that benefits both patients and the wider scientific community.
Aptamer Group PLC -
York, UK.
We support Aptamer Group in advancing their scientific ambitions in radiopharmaceutical development through active participation on their Scientific Advisory Board. Our role helps to guide strategy, foster innovation, and accelerate progress in this emerging field.